{"url":"https://lda.senate.gov/api/v1/filings/c0759ecb-c04f-4360-9be1-e8cf78136ecd/","filing_uuid":"c0759ecb-c04f-4360-9be1-e8cf78136ecd","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2017,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/c0759ecb-c04f-4360-9be1-e8cf78136ecd/print/","filing_document_content_type":"text/html","income":null,"expenses":"500000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Patrick Ghila","dt_posted":"2018-01-22T18:00:43.370000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"86 Morris Ave","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Summit","registrant_state":"NJ","registrant_zip":"07901","registrant":{"id":62893,"url":"https://lda.senate.gov/api/v1/registrants/62893/","house_registrant_id":35486,"name":"CELGENE CORPORATION","description":"8/1/2004","address_1":"86 Morris Ave","address_2":null,"address_3":null,"address_4":null,"city":"Summit","state":"NJ","state_display":"New Jersey","zip":"07901","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PATRICK GLIHA","contact_telephone":"+1 202-371-7559","dt_updated":"2022-04-06T16:07:46.068330-04:00"},"client":{"id":162110,"url":"https://lda.senate.gov/api/v1/clients/162110/","client_id":12,"name":"CELGENE CORPORATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"1899-12-30"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 1390, \"STRONGER Patents Act of 2017\", provisions regarding patent reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60343,"prefix":null,"prefix_display":null,"first_name":"PATRICK","nickname":null,"middle_name":null,"last_name":"GLIHA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61037,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66374,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"POLAK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1, \"Tax Cuts and Jobs Act\", provisions regarding corporate tax reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60343,"prefix":null,"prefix_display":null,"first_name":"PATRICK","nickname":null,"middle_name":null,"last_name":"GLIHA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66374,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"POLAK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 2051, \"FAST Generics Act of 2017\", provisions regarding REMS.\n\nH.R. 1409, \"Cancer Drug Parity Act of 2017\", regarding all provisions.\n\nH.R. 2077, \"Restoring the Patient's Voice Act of 2017\", Step Therapy / Fail First.\n\nS. 974/ H.R. 2212, \"CREATES Act of 2017\", provisions regarding REMS.\n\nH.R. 849, \"Protecting Seniors' Access to Medicare Act of 2017\", regarding IPAB.\n\nIssues relating to Medicare Part D / Part B and the Affordable Care Act.\n\nRegulation of Non-Biological Complex Drugs.\n\nIssues relating to cancer drug coverage parity.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":61037,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"SCHUMAKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":60343,"prefix":null,"prefix_display":null,"first_name":"PATRICK","nickname":null,"middle_name":null,"last_name":"GLIHA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66374,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"POLAK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}